Clinical trial Recruiting at 1 site Observational Women only

Registry to evaluate pitolisant use during pregnancy

Official title: WAKIX® (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring

Run by Harmony Biosciences Management, Inc. · NCT05536011 · Data updated 2026-11-12

This study is trying to see how using pitolisant during pregnancy affects mothers and their babies, and it's open to pregnant women with and without narcolepsy.

Quick facts

Study typeObservational
SexWomen only
Enrollment1329 (estimated)
SponsorHarmony Biosciences Management, Inc.
Industry-sponsored
Locations1 site (Morrisville, North Carolina)
StatusRecruiting
StartedAugust 24, 2021
Main results expectedJune 30, 2030
Study endsJune 30, 2030
Registry record updatedJune 12, 2026
Trial IDNCT05536011 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include pregnant women of any age who have been exposed to pitolisant or comparator products.

Probably not a fit

Patients who have already experienced pregnancy outcomes prior to contacting the registry will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The WAKIX Pregnancy Registry is a prospective, observational cohort study in the US that aims to assess the effects of pitolisant exposure during pregnancy on maternal, fetal, and infant outcomes. Pregnant women who consent to participate will have their data collected from routine medical records, with no additional tests required. The study includes women with and without narcolepsy who have been exposed to pitolisant or comparator products. The registry follows FDA guidelines for pregnancy exposure studies.

Why it matters

Potential benefit: If successful, this registry could provide valuable insights into the safety and effects of pitolisant during pregnancy, guiding treatment decisions for pregnant women with narcolepsy.

How similar studies have gone: While observational studies on medication exposure during pregnancy are common, this specific registry approach for pitolisant is novel and untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pregnant woman of any age
* Consent to participate
* Authorization for her HCP(s) to provide data to the registry
* For participants with a diagnosis of narcolepsy: exposure to at least one dose of pitolisant or one dose of a comparator product, or, unexposed to pitolisant or comparator products at any time during pregnancy (i.e., any pregnant woman with a diagnosis of narcolepsy)
* For participants without a diagnosis of narcolepsy: exposure to at least one dose of pitolisant or one dose of a comparator product at any time during pregnancy

Exclusion Criterion:

• Occurrence of pregnancy outcome prior to first contact with the Registry Coordination Center (RCC) (i.e., retrospectively enrolled)

Where it's running

  • Evidera (PPD)
    Morrisville, North Carolina, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.